KURA Stock — Kura Oncology, Inc.

Kura Oncology, Inc. (KURA)

Updated October 16, 2026.

KURA is a Stock. Total return is -39.5% over the past 11.1 years, 398.0 points behind SPY at 358.5%.

Kura Oncology is a clinical-stage biopharmaceutical company developing cancer treatments, including its first commercial product KOMZIFTI (ziftomenib), a menin inhibitor for blood cancers, along with additional candidates in clinical trials for solid tumors and cardiometabolic disorders. The company does not currently have an established distribution schedule. This security is suited for investors seeking exposure to oncology-focused biotech development, though it carries the inherent risks and volatility of early-stage pharmaceutical companies.

KURA performance versus SPY

Price and return data through 2026-10-16.

Total return is -39.5% over the past 11.1 years, 398.0 points behind SPY at 358.5%. Over the past year its total return — price change plus distributions reinvested — is -10.4%. Its deepest 1-year drawdown was 39.0%.

KURA key facts

Asset type

Stock

Asset class

Equity

Inception date

09/16/2015

Distribution frequency

None

Last close

$9.08 (as of 2026-10-16)

Market cap

$807,762,421

Average volume

1781329.0

Beta

0.469

Payout ratio

0.0%

EPS

$-3.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KURA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.0%.

Who may consider KURA — and who may not

It is a weaker fit for investors who need monthly cash flow (KURA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on KURA

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions